Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) vs Sana Biotechnology Inc (SANA) Price & Performance

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETFTrade
Sana Biotechnology IncTrade

Price performance (Past 24H)

Key statistics

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs Sana Biotechnology Inc — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.02, while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.

QDTYSANA
Sector
Income / Options OverlayHealth
52-Week High
$46.71$5.92
52-Week Low
$36.57$2.68
Market Cap
$879.40M
Enterprise Value
$853.59M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY trades at $39.53 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The stock faces immediate resistance at $40 and support at $39. Recent corporate actions include consistent weekly dividend distributions, with amounts ranging from $0.22 to $0.32 per share throughout 2026.

The outlook remains cautious given the bearish technical signals and lack of available fundamental data. While the consistent dividend payments provide some income stability, the absence of key financial metrics like P/E ratio and profitability measures limits fundamental analysis. Investors face uncertainty regarding the company's financial health and growth prospects without current earnings data.

Sana Biotechnology Inc

SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.

While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF

QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.

Read more on QDTY

About Sana Biotechnology Inc

Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.

Read more on SANA